10-QPeriod: Q3 FY2024

DANAHER CORP /DE/ Quarterly Report for Q3 Ended Sep 27, 2024

Filed October 22, 2024For Securities:DHR

Summary

Danaher Corporation's Q3 2024 Form 10-Q filing indicates a mixed performance across its segments, with overall revenues seeing a 3.0% increase year-over-year, driven by acquisitions and price increases, while core sales grew by a modest 0.5%. The Diagnostics segment was a key performer, demonstrating strong core sales growth. However, the Life Sciences and Biotechnology segments experienced core sales declines, with Life Sciences impacted by an impairment charge and increased acquisition dilution, and Biotechnology facing reduced demand and inventory rationalization from larger customers. Net earnings from continuing operations saw a year-over-year decline, impacted by intangible asset impairments and increased operating expenses. The company generated substantial operating cash flow, though it decreased compared to the prior year, largely due to lower net earnings and changes in working capital. Significant cash outflow was observed in financing activities, primarily driven by substantial share repurchases, alongside debt repayments. Danaher maintains a strong liquidity position with significant cash on hand, and expects its effective tax rate for the remainder of 2024 to be around 17.5%.

Financial Highlights

50 data points
Beta

Revenue

$5.80B

58.7% Gross Margin

Net Income

$818.00M

14.1% Net Margin

EPS (Diluted)

$1.12

Total Assets

$80.61B

Cash & Equivalents

$2.63B

Free Cash Flow

$1.22B

Financial Statements
Beta
Revenue$5.80B
Cost of Revenue$2.40B
Gross Profit$3.40B
R&D Expenses$383.00M
SG&A Expenses$2.06B
Operating Income$958.00M
Net Income$818.00M
EPS (Basic)$1.13
EPS (Diluted)$1.12
Shares Outstanding (Basic)723.00M
Shares Outstanding (Diluted)729.40M

Key Highlights

  • 1Overall revenue increased by 3.0% year-over-year in Q3 2024, with core sales growing by 0.5%.
  • 2The Diagnostics segment showed robust performance with 5.0% core sales growth in both Q3 and the nine-month period.
  • 3Life Sciences and Biotechnology segments experienced core sales declines of 2.0% and flat/declining core sales (Q3/nine-month) respectively, impacted by demand weakness and inventory adjustments.
  • 4Q3 2024 net earnings from continuing operations were $818 million, down from $940 million in Q3 2023, primarily due to intangible asset impairments and higher operating expenses.
  • 5The company repurchased approximately $5.2 billion of its common stock in the nine-month period ended September 27, 2024, significantly impacting financing cash flows.
  • 6Operating cash flow from continuing operations for the first nine months of 2024 was $4.7 billion, a 5% decrease from the prior year, influenced by lower net earnings and working capital changes.
  • 7A significant impairment charge of $222 million related to a trade name in the Life Sciences segment negatively impacted operating profit margins.
  • 8Danaher ended the period with approximately $2.6 billion in cash and cash equivalents, maintaining a strong liquidity position.

Frequently Asked Questions

The decrease in net earnings from continuing operations for the three and nine-month periods ended September 27, 2024, compared to the prior year, was primarily driven by intangible asset impairments, notably a $222 million charge related to a trade name in the Life Sciences segment, and increased operating expenses, partially offset by higher other income and gains from foreign currency translation.

The Diagnostics segment was a strong performer with 5.0% core sales growth, driven by molecular and clinical diagnostics. The Biotechnology segment saw flat core sales in Q3 but a decline over the nine-month period, with a recovery expected in Q4. The Life Sciences segment experienced a 2.0% core sales decline in Q3, impacted by weaker demand for equipment and a significant impairment charge, though acquisitions partially offset the revenue decrease.

Danaher anticipates a gradual recovery in the Biotechnology segment's bioprocessing business. Larger customers are returning to normal ordering patterns as they reduce excess inventory. However, smaller customers continue to conserve liquidity. The company expects high-single digit core revenue growth in Q4 2024 for this business, and a low-single digit core revenue decline for the full year 2024.

Danaher maintains substantial operating cash flow and holds approximately $2.6 billion in cash and cash equivalents as of September 27, 2024. The company plans to fund its operations, investments, and debt obligations through operating cash flow and available liquidity. Significant financing activities in the period included substantial share repurchases ($5.2 billion) and debt repayments, resulting in a net use of cash for financing activities.